HFS
VIR icon

Hantz Financial Services’s Vir Biotechnology VIR Stock Holding History

Hantz Financial Services’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29K Sell
2,881
-111
-4% -$1.06K ﹤0.01% 1841
2026
Q1 		$27K Buy
2,992
+606
+25% +$4.83K ﹤0.01% 1772
2025
Q4 		$14K Buy
2,386
+545
+30% +$3.25K ﹤0.01% 1915
2025
Q3 		$11K Buy
1,841
+585
+47% +$2.99K ﹤0.01% 1810
2025
Q2 		$6K Buy
1,256
+1,235
+5,881% +$6.62K ﹤0.01% 1714
2025
Q1 		$0 Buy
+21
New +$187 ﹤0.01% 1988
2024
Q3 		– Sell
-9
Closed – – 1188
2024
Q2 		$0 Hold
9
– – ﹤0.01% 1270
2024
Q1 		$0 Hold
9
– – ﹤0.01% 1299
2023
Q4 		$0 Hold
9
– – ﹤0.01% 1229
2023
Q3 		$0 Hold
9
– – ﹤0.01% 1189
2023
Q2 		$0 Hold
9
– – ﹤0.01% 1178
2023
Q1 		$0 Buy
+9
New +$230 ﹤0.01% 1203

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Hantz Financial Services's VIR Position: Q2 2026 in Review

Hantz Financial Services reduced its Vir Biotechnology (VIR) stake by 3.7% in Q2 2026, selling an estimated $1.06K and leaving 2,881 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #1841.

Hantz Financial Services first reported a position in VIR in Q1 2023 and has held it in 12 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Hantz Financial Services held 2,881 shares of Vir Biotechnology worth $29K as of Q2 2026.
  • Hantz Financial Services sold 111 Vir Biotechnology shares in Q2 2026, an estimated $1.06K.
  • Vir Biotechnology made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1841 holding.
  • Hantz Financial Services first reported a position in Vir Biotechnology in Q1 2023 and has held it in 12 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.